Sergei V. Tsaregorodtsev
Sergei V. Tsaregorodtsev has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Dmitrii N. Andreev
Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia
9 shared publications - Igor Veniaminovich Maev
Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia
8 shared publications - Aleksei K. Fomenko
Russian University of Medicine
7 shared publications - Andrey Vladimirovich Zaborovsky
Department of Pharmacology, Russian University of Medicine, 127473 Moscow, Russia
7 shared publications - Filipp S. Sokolov
Department of Pharmacology, Russian University of Medicine, 127473 Moscow, Russia
7 shared publications A. V. Zaborovskiy
Russian University of Medicine (ROSUNIMED)
3 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 78-93
Autophagy in the pathogenesis of metabolic dysfunction-associated fatty liver disease: Current evidence and therapeutic perspectives – a narrative review
Introduction . Metabolic dysfunction-associated fatty liver disease (MASLD) is the most common chronic liver disease, affecting about one third of the adult population worldwide. Autophagy is a key compensatory mechanism that maintains hepatocyte homeostasis under lipotoxic stress, and its impairment is regarded as an important element of MASLD pathogenesis. Aim. To summarize current evidence on the role of autophagy in the pathogenesis of MASLD and to assess the therapeutic potential of its pharmacological modulation. Materials and methods . A search of PubMed/MEDLINE, Scopus, Google Scholar and eLIBRARY.RU was performed for publications in Russian and English using keywords related to MASLD/NAFLD, autophagy, mitophagy, lipophagy and autophagy-modulating drugs. The review includes 112 sources: experimental and clinical studies, systematic reviews, meta-analyses and clinical guidelines. Results. The molecular mechanisms of macroautophagy, mitophagy, lipophagy, microautophagy and chaperone-mediated autophagy and their impairment in MASLD are reviewed. The effects of autophagy are cell-specific: protective in hepatocytes and Kupffer cells but profibrogenic in activated hepatic stellate cells. Metformin, gliflozins, GLP-1 receptor agonists and polyagonists, gliptins, PPAR agonists, berberine and quercetin mainly modulate the AMPK/mTOR/ULK axis, but evidence for most of them is mainly preclinical. Ursodeoxycholic acid has the most mature clinical evidence base: it stimulates AMPK-dependent lipophagy and mitophagy and reduces markers of cytolysis and cholestasis and non-invasive indices of steatosis and fibrosis. Conclusions . Autophagy is a promising therapeutic target in MASLD; however, its modulation should take cell specificity into account, and the clinical evidence base needs to be expanded.
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 78-93
Open AccessAutophagy in the pathogenesis of metabolic dysfunction-associated fatty liver disease: Current evidence and therapeutic perspectives – a narrative review
Introduction . Metabolic dysfunction-associated fatty liver disease (MASLD) is the most common chronic liver disease, affecting about one third of the adult population worldwide. Autophagy is a key compensatory mechanism that maintains hepatocyte homeostasis under lipotoxic stress, and its impairment is regarded as an important element of MASLD pathogenesis. Aim. To summarize current evidence on the role of autophagy in the pathogenesis of MASLD and to assess the therapeutic potential of its pharmacological modulation. Materials and methods . A search of PubMed/MEDLINE, Scopus, Google Scholar and eLIBRARY.RU was performed for publications in Russian and English using keywords related to MASLD/NAFLD, autophagy, mitophagy, lipophagy and autophagy-modulating drugs. The review includes 112 sources: experimental and clinical studies, systematic reviews, meta-analyses and clinical guidelines. Results. The molecular mechanisms of macroautophagy, mitophagy, lipophagy, microautophagy and chaperone-mediated autophagy and their impairment in MASLD are reviewed. The effects of autophagy are cell-specific: protective in hepatocytes and Kupffer cells but profibrogenic in activated hepatic stellate cells. Metformin, gliflozins, GLP-1 receptor agonists and polyagonists, gliptins, PPAR agonists, berberine and quercetin mainly modulate the AMPK/mTOR/ULK axis, but evidence for most of them is mainly preclinical. Ursodeoxycholic acid has the most mature clinical evidence base: it stimulates AMPK-dependent lipophagy and mitophagy and reduces markers of cytolysis and cholestasis and non-invasive indices of steatosis and fibrosis. Conclusions . Autophagy is a promising therapeutic target in MASLD; however, its modulation should take cell specificity into account, and the clinical evidence base needs to be expanded.
- Open Access
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 164-171
Micronutrient deficiencies in young women: Vitamin D, vitamin C, and iron – rapid screening
Introduction . Micronutrient deficiencies, particularly of vitamin D, vitamin C, and iron, are highly prevalent among women of reproductive age and are associated with impaired immune and hormonal function. Aim. To assess the prevalence of vitamin D deficiency, low vitamin C status, and reduced iron stores (as measured by ferritin) in young women aged 18–25 years, and to examine their association with risk factors. Material and methods . The study included 74 volunteers. Capillary blood and urine samples were collected once during a single screening visit. Micronutrient levels were determined using semi-quantitative rapid test kits (IMBIAN LLC): vitamin D and ferritin in whole capillary blood, and vitamin C in urine (colorimetrically). Results were interpreted using the manufacturer’s discrete categorical (colour-coded) scale rather than continuous reference intervals. The study has a pilot and screening nature and is not designed to evaluate the actual prevalence in the population. Results . In our sample (n = 74), vitamin D deficiency or insufficiency (Conclusion . Iron, vitamin D, and vitamin C deficiencies frequently coexist in young women, potentially contributing to impairments in immune, muscle, and reproductive function. Further prospective studies are needed to assess the effectiveness of combined preventive programmes; the findings substantiate the need for screening and targeted prevention taking modifiable risk factors into account. The weak but statistically significant association between the VDIRS risk questionnaire and rapid test results supports its potential utility for preliminary risk stratification prior to laboratory confirmation.
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 164-171
Open AccessMicronutrient deficiencies in young women: Vitamin D, vitamin C, and iron – rapid screening
Introduction . Micronutrient deficiencies, particularly of vitamin D, vitamin C, and iron, are highly prevalent among women of reproductive age and are associated with impaired immune and hormonal function. Aim. To assess the prevalence of vitamin D deficiency, low vitamin C status, and reduced iron stores (as measured by ferritin) in young women aged 18–25 years, and to examine their association with risk factors. Material and methods . The study included 74 volunteers. Capillary blood and urine samples were collected once during a single screening visit. Micronutrient levels were determined using semi-quantitative rapid test kits (IMBIAN LLC): vitamin D and ferritin in whole capillary blood, and vitamin C in urine (colorimetrically). Results were interpreted using the manufacturer’s discrete categorical (colour-coded) scale rather than continuous reference intervals. The study has a pilot and screening nature and is not designed to evaluate the actual prevalence in the population. Results . In our sample (n = 74), vitamin D deficiency or insufficiency (Conclusion . Iron, vitamin D, and vitamin C deficiencies frequently coexist in young women, potentially contributing to impairments in immune, muscle, and reproductive function. Further prospective studies are needed to assess the effectiveness of combined preventive programmes; the findings substantiate the need for screening and targeted prevention taking modifiable risk factors into account. The weak but statistically significant association between the VDIRS risk questionnaire and rapid test results supports its potential utility for preliminary risk stratification prior to laboratory confirmation.
- Open Access
- 21 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 114-123
Analysis of trace element composition of blood serum and oral fluid during periods of increased psycho-emotional stress
Introduction . Imbalances in macroand trace elements represent common forms of nutritional deficiency and may affect inflammatory responses, antioxidant defense, and the integrity of the gastrointestinal epithelial barrier. In students during the examination period, chronic stress, irregular dietary patterns, and insufficient sunlight exposure may contribute to the development of subclinical deficiency states. Aim . To assess the bioelemental status of students during the examination period based on macroand trace element concentrations in blood serum and oral fluid, and to evaluate inter-matrix relationships between corresponding elements. Materials and methods. Forty-five volunteers were enrolled. Fasting blood serum and oral fluid samples were collected once during the examination period. Concentrations of 35 elements were determined using inductively coupled plasma mass spectrometry (ICP-MS). A three-level within-reference interpretation scale was applied for serum data. Spearman correlation analysis was performed. Results. For most elements, values clustered within the mid-reference subrange or near the lower reference limit. Selenium deficiency was detected in 37/45 participants (82.2%), with pre-deficiency values in 7/45 (15.6%) and reference-range values in 1/45 (2.2%). Strong positive correlations in serum were observed for Mn–Fe (rS = 0.80), Na–Mg (0.78), Na–K (0.72), and Na–Zn (0.66), with moderate correlations for Mg–P (0.51) and P–Cu (0.49). Conclusions. A tendency toward reduced concentrations of several macroand trace elements was identified in students during the examination period, with the most pronounced changes observed for selenium. This may reflect the development of an unfavorable nutritional and metabolic background. The limited agreement between oral fluid and blood serum parameters does not support considering oral fluid a reliable surrogate marker of systemic microelement status. The use of a three-level interpretation scale may be helpful for identifying pre-deficiency states.
- 21 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 114-123
Open AccessAnalysis of trace element composition of blood serum and oral fluid during periods of increased psycho-emotional stress
Introduction . Imbalances in macroand trace elements represent common forms of nutritional deficiency and may affect inflammatory responses, antioxidant defense, and the integrity of the gastrointestinal epithelial barrier. In students during the examination period, chronic stress, irregular dietary patterns, and insufficient sunlight exposure may contribute to the development of subclinical deficiency states. Aim . To assess the bioelemental status of students during the examination period based on macroand trace element concentrations in blood serum and oral fluid, and to evaluate inter-matrix relationships between corresponding elements. Materials and methods. Forty-five volunteers were enrolled. Fasting blood serum and oral fluid samples were collected once during the examination period. Concentrations of 35 elements were determined using inductively coupled plasma mass spectrometry (ICP-MS). A three-level within-reference interpretation scale was applied for serum data. Spearman correlation analysis was performed. Results. For most elements, values clustered within the mid-reference subrange or near the lower reference limit. Selenium deficiency was detected in 37/45 participants (82.2%), with pre-deficiency values in 7/45 (15.6%) and reference-range values in 1/45 (2.2%). Strong positive correlations in serum were observed for Mn–Fe (rS = 0.80), Na–Mg (0.78), Na–K (0.72), and Na–Zn (0.66), with moderate correlations for Mg–P (0.51) and P–Cu (0.49). Conclusions. A tendency toward reduced concentrations of several macroand trace elements was identified in students during the examination period, with the most pronounced changes observed for selenium. This may reflect the development of an unfavorable nutritional and metabolic background. The limited agreement between oral fluid and blood serum parameters does not support considering oral fluid a reliable surrogate marker of systemic microelement status. The use of a three-level interpretation scale may be helpful for identifying pre-deficiency states.
- Open Access
- 22 December 2025
- Published by National Research Mordovia State University MRSU in Medicine and Biotechnology
- Vol. 1 (4) , 356-375
Analysis of the Current State and Trends in the Field of Pharmacological Hepatoprotection
Introduction. Hepatic disorders constitute a significant global health challenge, underscoring the critical need for effective therapeutic strategies. Hepatoprotective agents play a pivotal role in management; however, their efficacy is frequently constrained by pharmacokinetic limitations. The objective of this review is to provide a systematic analysis of contemporary approaches to hepatoprotection, encompassing an evaluation of existing pharmacological classes, combination treatment regimens, and emerging directions, such as the application of nanotechnology to enhance the bioavailability and therapeutic potential of active pharmaceutical ingredients. Materials and methods. A review and analysis of contemporary scientific literature pertaining to liver disease epidemiology, the classification of hepatoprotective agents, and the application of nanotechnology for the enhancement of their bioavailability was conducted. The literature search was performed across the PubMed, Springer Link, and eLibrary databases, with selection criteria limited to relevant publications from the past decade. Results. Despite the diversity of hepatoprotector classes with distinct mechanisms of action, their clinical efficacy is often constrained by low bioavailability. Analysis reveals that the most promising strategy to overcome these limitations is the application of nanotechnology to create targeted drug delivery systems. Discussion and conclusion. Current evidence indicates a lack of a universally effective hepatoprotective agent, with many combination regimens requiring further investigation. There is a demonstrated need both to optimize existing therapeutics through nano-engineering approaches and to continue the search for novel pharmacologically active compounds.
- 22 December 2025
- Published by National Research Mordovia State University MRSU in Medicine and Biotechnology
- Vol. 1 (4) , 356-375
Open AccessAnalysis of the Current State and Trends in the Field of Pharmacological Hepatoprotection
Introduction. Hepatic disorders constitute a significant global health challenge, underscoring the critical need for effective therapeutic strategies. Hepatoprotective agents play a pivotal role in management; however, their efficacy is frequently constrained by pharmacokinetic limitations. The objective of this review is to provide a systematic analysis of contemporary approaches to hepatoprotection, encompassing an evaluation of existing pharmacological classes, combination treatment regimens, and emerging directions, such as the application of nanotechnology to enhance the bioavailability and therapeutic potential of active pharmaceutical ingredients. Materials and methods. A review and analysis of contemporary scientific literature pertaining to liver disease epidemiology, the classification of hepatoprotective agents, and the application of nanotechnology for the enhancement of their bioavailability was conducted. The literature search was performed across the PubMed, Springer Link, and eLibrary databases, with selection criteria limited to relevant publications from the past decade. Results. Despite the diversity of hepatoprotector classes with distinct mechanisms of action, their clinical efficacy is often constrained by low bioavailability. Analysis reveals that the most promising strategy to overcome these limitations is the application of nanotechnology to create targeted drug delivery systems. Discussion and conclusion. Current evidence indicates a lack of a universally effective hepatoprotective agent, with many combination regimens requiring further investigation. There is a demonstrated need both to optimize existing therapeutics through nano-engineering approaches and to continue the search for novel pharmacologically active compounds.
- Open Access
- 17 October 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 65-73
Clinical, serological and morphological characterization of chronic gastritis in patients with dyspepsia: Data from a prospective urban population analysis
Introduction . Chronic gastritis remains one of the most prevalent disorders of the upper gastrointestinal tract, with H. pylori playing a key role in its pathogenesis. Aim . To provide a comprehensive clinical, morphological, and serological assessment of the gastric mucosa in patients with chronic gastritis presenting with dyspepsia. Materials and methods . This prospective single-center study (Moscow, 2021–2025) enrolled 309 patients presenting with dyspepsia. All participants underwent a standardized diagnostic algorithm comprising a 13C-urea breath test (13C-UBT); esophagogastroduodenoscopy (EGD) with multifocal biopsies and OLGA staging; the GastroPanel® serological test (pepsinogen I, pepsinogen II, gastrin-17, and IgG antibodies to H. pylori ); and the 7×7 symptom scale. Results . H. pylori infection was confirmed in 147/309 patients (47.6%). Among H. pylori -positive patients, atrophic chronic gastritis predominated (69.4%), whereas in H. pylori -negative patients superficial (non-atrophic) gastritis was most frequent (91.4%) (p < 0.0001). Within H. pylori -associated atrophic gastritis, early OLGA stages I-II prevailed (86.0%). In the H. pylori -negative subgroup with atrophic gastritis, median PGI was reduced versus superficial gastritis (35.9 vs 78.3 µg/L; p < 0.0001) with moderate changes in PGII and a tendency toward higher G-17. In H. pylori -positive patients, eradication therapy was followed by a significant decrease in total 7×7 scores. ROC analysis of the PGI/PGII ratio for detecting advanced atrophy (OLGA III/IV) yielded an AUC of 0.820 (95% CI, 0.748–0.878), sensitivity 80.0%, and specificity 81.1% at a cut-off ≤ 2. The per-protocol eradication rate was 85.42% (82/96); the safety profile was predominantly mild to moderate (adverse events in 26.0%). Conclusions . An integrated approach combining OLGA staging, GastroPanel® biomarkers, and the 7×7 scale provides consistent, reproducible stratification of chronic gastritis and optimizes selection for invasive verification. The PGI/PGII ratio shows high diagnostic value for identifying advanced stages of gastric mucosal atrophy (OLGA III/IV), and H. pylori eradication is associated with clinically meaningful symptom improvement.
- 17 October 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 65-73
Open AccessClinical, serological and morphological characterization of chronic gastritis in patients with dyspepsia: Data from a prospective urban population analysis
Introduction . Chronic gastritis remains one of the most prevalent disorders of the upper gastrointestinal tract, with H. pylori playing a key role in its pathogenesis. Aim . To provide a comprehensive clinical, morphological, and serological assessment of the gastric mucosa in patients with chronic gastritis presenting with dyspepsia. Materials and methods . This prospective single-center study (Moscow, 2021–2025) enrolled 309 patients presenting with dyspepsia. All participants underwent a standardized diagnostic algorithm comprising a 13C-urea breath test (13C-UBT); esophagogastroduodenoscopy (EGD) with multifocal biopsies and OLGA staging; the GastroPanel® serological test (pepsinogen I, pepsinogen II, gastrin-17, and IgG antibodies to H. pylori ); and the 7×7 symptom scale. Results . H. pylori infection was confirmed in 147/309 patients (47.6%). Among H. pylori -positive patients, atrophic chronic gastritis predominated (69.4%), whereas in H. pylori -negative patients superficial (non-atrophic) gastritis was most frequent (91.4%) (p < 0.0001). Within H. pylori -associated atrophic gastritis, early OLGA stages I-II prevailed (86.0%). In the H. pylori -negative subgroup with atrophic gastritis, median PGI was reduced versus superficial gastritis (35.9 vs 78.3 µg/L; p < 0.0001) with moderate changes in PGII and a tendency toward higher G-17. In H. pylori -positive patients, eradication therapy was followed by a significant decrease in total 7×7 scores. ROC analysis of the PGI/PGII ratio for detecting advanced atrophy (OLGA III/IV) yielded an AUC of 0.820 (95% CI, 0.748–0.878), sensitivity 80.0%, and specificity 81.1% at a cut-off ≤ 2. The per-protocol eradication rate was 85.42% (82/96); the safety profile was predominantly mild to moderate (adverse events in 26.0%). Conclusions . An integrated approach combining OLGA staging, GastroPanel® biomarkers, and the 7×7 scale provides consistent, reproducible stratification of chronic gastritis and optimizes selection for invasive verification. The PGI/PGII ratio shows high diagnostic value for identifying advanced stages of gastric mucosal atrophy (OLGA III/IV), and H. pylori eradication is associated with clinically meaningful symptom improvement.
- Open Access
- 28 August 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (8) , 660-667
Study on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors
Aim. To evaluate the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 versus rifaximin monotherapy in patients with small intestinal bacterial overgrowth (SIBO) associated with long-term proton pump inhibitor (PPI) use. Materials and methods. A prospective comparative study with two parallel groups was conducted. Eligible patients were those on continuous long-term PPI therapy ( 3 months) with confirmed SIBO. SIBO was diagnosed in all patients using a lactulose Hydrogen/Methane Breath Test (HMBT). Symptom severity was assessed using the validated "7 × 7" Questionnaire, and Quality of Life (QoL) was evaluated using the SF-36 Health Status Survey. Enrolled patients were randomized into two groups based on a 7-day treatment regimen: Group 1 received rifaximin (400 mg twice daily); Group 2 received rifaximin (400 mg twice daily) plus the probiotic Saccharomyces boulardii CNCM I-745 (Enterol® drug product, Biocodex, France; 500 mg twice daily). SIBO eradication was confirmed via repeat lactulose HMBT, and symptom severity/QoL were reassessed 4 weeks after treatment completion. Results. 108 patients were enrolled (mean age 38.7 ± 8.9 years; 65.7% female). Mean PPI treatment duration at enrollment was 4.81 months (95% confidence interval 4.15–5.46). At 4-week follow-up, repeat lactulose HMBT showed SIBO persistence in 41.5% of Group 1 (n = 22/53) versus 21.8% in Group 2 (n = 12/55; p = 0.038). Statistically significant resolution of diarrhea was observed only in Group 2 (p = 0.033). The final median "7 × 7" Questionnaire score was significantly lower in Group 2 (p = 0.0010). Both groups showed significant trends toward QoL improvement on the SF-36 survey. Conclusion. This prospective comparative study demonstrates that combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 appears more effective than rifaximin monotherapy for SIBO eradication, symptom regression, and QoL improvement in patients with PPI-associated SIBO.
- 28 August 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (8) , 660-667
Open AccessStudy on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors
Aim. To evaluate the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 versus rifaximin monotherapy in patients with small intestinal bacterial overgrowth (SIBO) associated with long-term proton pump inhibitor (PPI) use. Materials and methods. A prospective comparative study with two parallel groups was conducted. Eligible patients were those on continuous long-term PPI therapy ( 3 months) with confirmed SIBO. SIBO was diagnosed in all patients using a lactulose Hydrogen/Methane Breath Test (HMBT). Symptom severity was assessed using the validated "7 × 7" Questionnaire, and Quality of Life (QoL) was evaluated using the SF-36 Health Status Survey. Enrolled patients were randomized into two groups based on a 7-day treatment regimen: Group 1 received rifaximin (400 mg twice daily); Group 2 received rifaximin (400 mg twice daily) plus the probiotic Saccharomyces boulardii CNCM I-745 (Enterol® drug product, Biocodex, France; 500 mg twice daily). SIBO eradication was confirmed via repeat lactulose HMBT, and symptom severity/QoL were reassessed 4 weeks after treatment completion. Results. 108 patients were enrolled (mean age 38.7 ± 8.9 years; 65.7% female). Mean PPI treatment duration at enrollment was 4.81 months (95% confidence interval 4.15–5.46). At 4-week follow-up, repeat lactulose HMBT showed SIBO persistence in 41.5% of Group 1 (n = 22/53) versus 21.8% in Group 2 (n = 12/55; p = 0.038). Statistically significant resolution of diarrhea was observed only in Group 2 (p = 0.033). The final median "7 × 7" Questionnaire score was significantly lower in Group 2 (p = 0.0010). Both groups showed significant trends toward QoL improvement on the SF-36 survey. Conclusion. This prospective comparative study demonstrates that combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 appears more effective than rifaximin monotherapy for SIBO eradication, symptom regression, and QoL improvement in patients with PPI-associated SIBO.
- Open Access
- 3 March 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (3) , 194
Gut Mycobiome Changes During COVID-19 Disease
The majority of metagenomic studies are based on the study of bacterial biota. At the same time, the COVID-19 pandemic has prompted interest in the study of both individual fungal pathogens and fungal communities (i.e., the mycobiome) as a whole. Here, in this work, we investigated the human gut mycobiome during COVID-19. Stool samples were collected from patients at two time points: at the time of admission to the hospital (the first time point) and at the time of discharge from the hospital (the second time point). The results of this study revealed that Geotrichum sp. is more represented in a group of patients with COVID-19. Therefore, Geotrichum sp. is elevated in patients at the time of admission to the hospital and underestimated at the time of discharge. Additionally, the influence of factors associated with the diversity of fungal gut microbiota was separately studied, including disease severity and age factors.
- 3 March 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (3) , 194
Open AccessGut Mycobiome Changes During COVID-19 Disease
The majority of metagenomic studies are based on the study of bacterial biota. At the same time, the COVID-19 pandemic has prompted interest in the study of both individual fungal pathogens and fungal communities (i.e., the mycobiome) as a whole. Here, in this work, we investigated the human gut mycobiome during COVID-19. Stool samples were collected from patients at two time points: at the time of admission to the hospital (the first time point) and at the time of discharge from the hospital (the second time point). The results of this study revealed that Geotrichum sp. is more represented in a group of patients with COVID-19. Therefore, Geotrichum sp. is elevated in patients at the time of admission to the hospital and underestimated at the time of discharge. Additionally, the influence of factors associated with the diversity of fungal gut microbiota was separately studied, including disease severity and age factors.
- 5 September 2024
- Published by Alfmed LLC in Medical alphabet
- No. 16,p. 58‑64
The use of sweeteners and sugar substitutes in the food industry. Sweet proteins as a new alternative
This review examines the consequences of excessive consumption of sweet products on human health and explores the potential of sugar substitutes and intensive sweeteners, including sweet proteins, as their healthier alternatives. Analyzing statistical data on the prevalence of diabetes and obesity, the study highlights the health risks associated with high sugar intake. An extensive review of the properties of various sugar substitutes and sweeteners has been conducted, focusing on their glycemic index and sweetness level. Special attention is given to sweet proteins, such as monellin and brazzein, their structure, and biological effects. Sweet proteins have a significantly high sweetness index and can serve as an alternative to traditional sugar in food production. However, their application in the food or pharmaceutical industry is limited. The study emphasizes the potential of sugar substitutes and sweeteners, especially sweet proteins, in developing food products by reducing sugar content. Nonetheless, further research is required to ensure the safety of sweet proteins and understand their long-term effects on human health.
- 5 September 2024
- Published by Alfmed LLC in Medical alphabet
- No. 16,p. 58‑64
The use of sweeteners and sugar substitutes in the food industry. Sweet proteins as a new alternative
This review examines the consequences of excessive consumption of sweet products on human health and explores the potential of sugar substitutes and intensive sweeteners, including sweet proteins, as their healthier alternatives. Analyzing statistical data on the prevalence of diabetes and obesity, the study highlights the health risks associated with high sugar intake. An extensive review of the properties of various sugar substitutes and sweeteners has been conducted, focusing on their glycemic index and sweetness level. Special attention is given to sweet proteins, such as monellin and brazzein, their structure, and biological effects. Sweet proteins have a significantly high sweetness index and can serve as an alternative to traditional sugar in food production. However, their application in the food or pharmaceutical industry is limited. The study emphasizes the potential of sugar substitutes and sweeteners, especially sweet proteins, in developing food products by reducing sugar content. Nonetheless, further research is required to ensure the safety of sweet proteins and understand their long-term effects on human health.
- 11 May 2024
- Published by Alfmed LLC in Medical alphabet
- No. 11,p. 7-13
Evaluation of the dynamics of oral pathogenic microbiota in COVID-19 patients by genomic sequencing after application of foam with antimicrobial action
Relevance. The COVID-19 pandemic caused by the SARS-CoV-2 virus has demonstrated the critical importance of understanding the mechanisms of transmission and finding effective methods of prevention. Particular attention has been paid to the role of oral hygiene, as the oral cavity serves as a major route of transmission. Studies show that the composition of the oral microbiota can influence the course and outcome of COVID-19 disease. Therefore, there is a need to study the effects of oral antiseptics on the microbiome, which may offer new opportunities for the prevention and treatment of this disease.Objective. The aim of this study is to evaluate the effectiveness of the oral cleansing foam «Parodontol PROF» in reducing the pathogenic microflora of the oral cavity in patients with COVID-19 and to assess its effect on the risk of secondary infections.Materials and methods. The study was conducted on the basis of the Clinical Medical Centre «Kuskovo» of Russian University of Medicine. It included 450 patients with a confirmed diagnosis of COVID-19. The participants were divided into two groups: the test group used oral cleansing foam, while the control group used no additional oral hygiene. Comparative analyses of the taxonomic composition of the oropharyngeal microbiota and dental plaque before and after the use of the cleansing foam were performed.Results. The study showed that patients who regularly used the cleansing foam «Parodontol PROF» had a significant decrease in the representation of pathogens, including Mycoplasma, and an increase in the number of beneficial commensals such as Lactococcus and Lactobacillus. These changes indicate the potential efficacy of this product to improve oral hygiene and reduce the risk of secondary infections.Conclusion. The study supports the hypothesis that improving oral hygiene with specialised antiseptic agents, such as a cleansing foam, may help to reduce pathogenic microflora in the oral cavity in patients with COVID-19. This, in turn, may reduce the risk of pathogen migration into the lower respiratory tract and the development of secondary infections. The findings emphasise the importance of further research in this area and the development of comprehensive approaches to oral hygiene management in the context of infectious diseases.
- 11 May 2024
- Published by Alfmed LLC in Medical alphabet
- No. 11,p. 7-13
Evaluation of the dynamics of oral pathogenic microbiota in COVID-19 patients by genomic sequencing after application of foam with antimicrobial action
Relevance. The COVID-19 pandemic caused by the SARS-CoV-2 virus has demonstrated the critical importance of understanding the mechanisms of transmission and finding effective methods of prevention. Particular attention has been paid to the role of oral hygiene, as the oral cavity serves as a major route of transmission. Studies show that the composition of the oral microbiota can influence the course and outcome of COVID-19 disease. Therefore, there is a need to study the effects of oral antiseptics on the microbiome, which may offer new opportunities for the prevention and treatment of this disease.Objective. The aim of this study is to evaluate the effectiveness of the oral cleansing foam «Parodontol PROF» in reducing the pathogenic microflora of the oral cavity in patients with COVID-19 and to assess its effect on the risk of secondary infections.Materials and methods. The study was conducted on the basis of the Clinical Medical Centre «Kuskovo» of Russian University of Medicine. It included 450 patients with a confirmed diagnosis of COVID-19. The participants were divided into two groups: the test group used oral cleansing foam, while the control group used no additional oral hygiene. Comparative analyses of the taxonomic composition of the oropharyngeal microbiota and dental plaque before and after the use of the cleansing foam were performed.Results. The study showed that patients who regularly used the cleansing foam «Parodontol PROF» had a significant decrease in the representation of pathogens, including Mycoplasma, and an increase in the number of beneficial commensals such as Lactococcus and Lactobacillus. These changes indicate the potential efficacy of this product to improve oral hygiene and reduce the risk of secondary infections.Conclusion. The study supports the hypothesis that improving oral hygiene with specialised antiseptic agents, such as a cleansing foam, may help to reduce pathogenic microflora in the oral cavity in patients with COVID-19. This, in turn, may reduce the risk of pathogen migration into the lower respiratory tract and the development of secondary infections. The findings emphasise the importance of further research in this area and the development of comprehensive approaches to oral hygiene management in the context of infectious diseases.
- Open Access
- 1 May 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (5) , 996
Microbial Signatures in COVID-19: Distinguishing Mild and Severe Disease via Gut Microbiota
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global healthcare, underscoring the importance of exploring the virus’s effects on infected individuals beyond treatments and vaccines. Notably, recent findings suggest that SARS-CoV-2 can infect the gut, thereby altering the gut microbiota. This study aimed to analyze the gut microbiota composition differences between COVID-19 patients experiencing mild and severe symptoms. We conducted 16S rRNA metagenomic sequencing on fecal samples from 49 mild and 43 severe COVID-19 cases upon hospital admission. Our analysis identified a differential abundance of specific bacterial species associated with the severity of the disease. Severely affected patients showed an association with Enterococcus faecium, Akkermansia muciniphila, and others, while milder cases were linked to Faecalibacterium prausnitzii, Alistipes putredinis, Blautia faecis, and additional species. Furthermore, a network analysis using SPIEC-EASI indicated keystone taxa and highlighted structural differences in bacterial connectivity, with a notable disruption in the severe group. Our study highlights the diverse impacts of SARS-CoV-2 on the gut microbiome among both mild and severe COVID-19 patients, showcasing a spectrum of microbial responses to the virus. Importantly, these findings align, to some extent, with observations from other studies on COVID-19 gut microbiomes, despite variations in methodologies. The findings from this study, based on retrospective data, establish a foundation for future prospective research to confirm the role of the gut microbiome as a predictive biomarker for the severity of COVID-19.
- 1 May 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (5) , 996
Open AccessMicrobial Signatures in COVID-19: Distinguishing Mild and Severe Disease via Gut Microbiota
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global healthcare, underscoring the importance of exploring the virus’s effects on infected individuals beyond treatments and vaccines. Notably, recent findings suggest that SARS-CoV-2 can infect the gut, thereby altering the gut microbiota. This study aimed to analyze the gut microbiota composition differences between COVID-19 patients experiencing mild and severe symptoms. We conducted 16S rRNA metagenomic sequencing on fecal samples from 49 mild and 43 severe COVID-19 cases upon hospital admission. Our analysis identified a differential abundance of specific bacterial species associated with the severity of the disease. Severely affected patients showed an association with Enterococcus faecium, Akkermansia muciniphila, and others, while milder cases were linked to Faecalibacterium prausnitzii, Alistipes putredinis, Blautia faecis, and additional species. Furthermore, a network analysis using SPIEC-EASI indicated keystone taxa and highlighted structural differences in bacterial connectivity, with a notable disruption in the severe group. Our study highlights the diverse impacts of SARS-CoV-2 on the gut microbiome among both mild and severe COVID-19 patients, showcasing a spectrum of microbial responses to the virus. Importantly, these findings align, to some extent, with observations from other studies on COVID-19 gut microbiomes, despite variations in methodologies. The findings from this study, based on retrospective data, establish a foundation for future prospective research to confirm the role of the gut microbiome as a predictive biomarker for the severity of COVID-19.